Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Ethoxyamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxyamine SCHEMBL28307040 | 0.95 | — | — | |
| Ethoxyamine SCHEMBL31471 | 0.91 | — | — | |
| Ethoxyamine SCHEMBL10397176 | 0.87 | — | — | |
| Ethoxyamine SCHEMBL28425226 | 0.86 | — | — | |
| Ethoxyamine SCHEMBL28598862 | 0.86 | — | — | |
| Ethoxyamine SCHEMBL4245375 | 0.86 | — | — | |
| Ethoxyamine SCHEMBL27930346 | 0.86 | — | — | |
| Ethoxyamine SCHEMBL8021795 | 0.86 | — | — | |
| Ethoxyamine SCHEMBL38077 | 0.86 | — | — | |
| Ethoxyamine SCHEMBL27759466 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042754-A1 | Substituted Bicyclic Heteroaryl Sulfonamide Derivatives for the Treatment of Cancer | NODUS ONCOLOGY LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20250346938-A1 | ATP-DEPENDENT C-TERMINAL MODIFICATION OF POLYPEPTIDES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-11-13 | — | — | US | disclosed |
| CN-119824580-A | Fiber oiling agent with antistatic property and preparation method thereof | 江苏悦孚油品有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4311829-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Nodus Oncology Limited (GB) | 2024-01-31 | — | — | EP | disclosed |
| US-20220298133-A1 | OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| US-11208396-B2 | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| EP-3797778-A1 | OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | Heptares Therapeutics Limited (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-20200165220-A1 | OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| EP-3370828-B1 | OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2020-04-15 | — | — | EP | disclosed |
| EP-2342182-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-11-14 | — | — | EP | disclosed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | disclosed |
| EP-2342182-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2011-07-13 | — | — | EP | disclosed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| WO-2010028655-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-18 | — | — | WO | disclosed |